Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5)Homo sapiens (Human)Recombinant protein

FRCP2; Irisin; Fibronectin type III repeat-containing protein 2

  • Product No.RPN576Hu01
  • Organism SpeciesHomo sapiens (Human)Same name, Different species.
  • SourceProkaryotic expression
  • HostE.coli
  • Endotoxin Level<1.0EU per 1µg (determined by the LAL method)
  • Subcellular LocationMembrane
  • Predicted Molecular Mass16.6kDa
  • Accurate Molecular Mass18kDa(Analysis of differences refer to the manual)
  • Residues & TagsLeu2~Ile137 with N-terminal His Tag
  • Buffer Formulation20mM Tris, 150mM NaCl,pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • TraitsFreeze-dried powder
  • Purity> 90%
  • Isoelectric Point6.2
  • ApplicationsSDS-PAGE; WB; ELISA; IP; CoIP; Purification; Amine Reactive Labeling.
  • DownloadInstruction Manual
  • UOM10ug50ug200ug1mg1g
  • FOBUS$ 175US$ 438US$ 876US$ 2628US$ 65700
  • Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5)Package and Components
  • Recombinant Fibronectin Type III Domain Containing Protein 5 (FNDC5)Package and Components
    • RPN576Hu01.jpgSDS-PAGE
    • CertificateISO9001: 2008, ISO13485: 2003 Registered

    SEQUENCE

    USAGE

    Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

    STORAGE

    Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.

    STABILITY

    The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

    Reference

    • Diabetes Research and Clinical PracticeSerum irisin levels in new-onset type 2 diabetesPubMed: 23369227
    • Journal of diabetes and its complicationsLower circulating irisin is associated with type 2 diabetes mellitusPubmed: 23619195
    • Horm Metab Res.Inconsistency in circulating irisin levels: what is really happeningPubmed:24459033
    • Int J Obes (Lond).Leptin administration activates irisin-induced myogenesis via nitric oxide-dependent mechanisms, but reduces its effect on subcutaneous fat browning in micePubmed:25199621
    • Molecular and Cellular EndocrinologyFenofibrate (PPARalpha agonist) induces beige cell formation in subcutaneous white adipose tissue from diet-induced male obese micePubmed:25576856
    • journal of diabetesLower irisin level in patients with type 2 diabetes mellitus: A case-control study and meta-analysisPubMed: 25494632
    • The Journal of Maternal-Fetal & Neonatal MedicineMaternal circulating levels of irisin in intrahepatic cholestasis of pregnancyPubMed: 26689349
    • Hormone and Metabolic ResearchLower Circulating Irisin Level in Patients with Diabetes Mellitus: A Systematic Review and Meta-AnalysisPubmed:27300472